- Tytuł:
- Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Infectious Diseases June 2021 21(6):813-822
Czasopismo naukowe